Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (271-280 of 319) with videos related to

Pageof 32
Sort By:
The Journal of Urology|November 12, 2003
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatmentPeter R Carroll, David A Benaron, George Blackledge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge ConferenceRobert E Coleman, Theresa A Guise, Allan Lipton, et al.
European Urology|December 16, 2022
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]Martin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Urology|September 13, 2015
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08Justin C Voog, Rebecca Paulus, William U Shipley, et al.
European Urology|September 11, 2022
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS TrialMartin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Urology|September 10, 2020
Apalutamide and Overall Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2019
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate CancerWolfgang P Fendler, Manuel Weber, Amir Iravani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerDaniel C Danila, Michael J Morris, Johann S de Bono, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2026
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trialKarim Fizazi, Matthew R Smith, Maha Hussain, et al.
Lancet (London, England)|November 19, 2011
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialMatthew R Smith, Fred Saad, Robert Coleman, et al.
Pageof 32

Showing results (271-280 of 319) with videos related to

Sort By:
Pageof 32
The Journal of Urology|November 12, 2003
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatmentPeter R Carroll, David A Benaron, George Blackledge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge ConferenceRobert E Coleman, Theresa A Guise, Allan Lipton, et al.
European Urology|December 16, 2022
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]Martin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Urology|September 13, 2015
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08Justin C Voog, Rebecca Paulus, William U Shipley, et al.
European Urology|September 11, 2022
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS TrialMartin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Urology|September 10, 2020
Apalutamide and Overall Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2019
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate CancerWolfgang P Fendler, Manuel Weber, Amir Iravani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerDaniel C Danila, Michael J Morris, Johann S de Bono, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2026
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trialKarim Fizazi, Matthew R Smith, Maha Hussain, et al.
Lancet (London, England)|November 19, 2011
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialMatthew R Smith, Fred Saad, Robert Coleman, et al.
Pageof 32